Altius Bioventures Initiates Fundraising for Altius Bioventures Fund I

VANCOUVER, BC / ACCESSWIRE / November 14, 2023 / Altius Bioventures, has launched a fundraising campaign for Altius Bioventures Fund I, targeting a total raise of US$20 million, with an initial close of US$10 million.

Altius Bioventures Fund I, in conjunction with its connected accelerator program, Altius Bioventures Racer, will focus on investing in and building early-stage companies aimed at delivering transformative technologies, tools and services related to advanced therapies manufacturing and supply chain solutions, with the objectives of expediting commercial scalability, lowering cost-of-goods, and broadening global access to these life-saving therapies. All Altius Bioventures Fund I, portfolio companies will be part of the Altius Bioventures Racer, an accelerator program created to enable Altius' leadership to take provide active direction to involvement in the definition and execution of value catalysts for the Fund's portfolio companies.

"We are confident that a dedicated focus on tools, technologies, and services in this rapidly expanding market offers exceptional investment and return opportunities. We are operating in an industry that has now attained a level of maturity sufficient to attract the attention of significant capital and large companies searching for highly innovative, low-risk solutions to enhance the commercial scaling of these revolutionary treatments to patient when and where they need them," said Emmanuel Grillot, Managing Director and partner at Altius Bioventures. "In recent years, we've witnessed an increasing number of substantial commercial deals involving companies focused on addressing manufacturing, logistics, and cost pain points currently challenging the scalability, affordability, and accessibility of these therapies. Innovations focused on solutions to these issues are producing significant returns for early investors."

Altius Bioventures Fund I, together with Altius Bioventures Racer, will provide portfolio companies with more than just financial support - it has been designed to offer active value creation and access to an extensive and experienced global support network of experts, leaders and deal-makers. Each portfolio company in Altius Bioventures Fund I will be required to take part in a one-year intensive accelerator program tailored to leverage their unique potential. This approach will lead to the maturation of a diverse range of asset-centric, technology-driven, and solutions-focused companies, all with a shared focus on enabling critical transformations in the rapidly growing advanced therapy industry.

The co-founding partners of Altius Bioventures have been involved in building and supporting innovative advanced therapy startups for over two decades, and have extensive capital markets, M&A and financing experience. Together with Emmanuel Grillot, the four co-founding partners in Altius Bioventures Fund are Blair Jordan, Lee Buckler, Troels Jordansen, and Rakesh Verma.

About Altius Bioventures

Altius Bioventures is an innovative venture firm specializing in investing in and building advanced therapy technologies, tools, and service companies. Founded by an experienced and cross-functional team, the firm leverages a disciplined, active value-creation approach to nurture startups in the cell and gene therapy space. We offer not only financial backing but also a global support ecosystem, including an intensive one-year accelerator program. Our mission is to rigorously select and focus investments on the most compelling opportunities to build scalable businesses and realize value by providing transformative technologies and platforms to the advanced therapy industry. For more information, please visit www.altiusbioventures.vc

If you are an investor, please contact:
Emmanuel Grillot: emmanuel@altiusbioventures.vc ; +33 670 568 236

SOURCE: Altius Bioventures